There are many new immunotherapeutic drugs for cancer in the research pipeline. Too few patients are available to fill the clinical trials, as many are receiving treatment from physicians outside of the research institutions where trials are being held. In addition, many pharmaceutical companies are researching similar drugs, meaning there can be significant competition for the patients who are available. How should this problem be solved? http://nyti.ms/2v5A89E
- Free WCG Foundation webinars offer insights on speeding access to experimental drugs for intermediate-size patient populations
- Do supercentenarians, people who live to 110 years and older, have something special in their genetic code?
- To call in or go in to work when sick? This time of year, that’s the question.
- Could #breastcancer be prevented from spreading to the brain?
- #AntibioticResistance could lead to dangerous outcomes. What can be done to prevent this?